MiroHealth
Follow the data
The brain is our most vital organ.
We help you treat it that way.
We help you treat it that way.
A new standard of brain healthcare
Miro is committed to scientific integrity
and
transparency. To safeguard that
commitment, we
display analyses of
research programs sponsored
by Miro.
Analyses are ongoing and continually
update with the growth of our data set.
and
transparency. To safeguard that
commitment, we
display analyses of
research programs sponsored
by Miro.
Analyses are ongoing and continually
update with the growth of our data set.
Learn more about Miro's philosophy
Historical studies and results
February 2017
The discrimination between
subjects
with mild cognitive
impairment and normal controls
subjects
with mild cognitive
impairment and normal controls
Demographics
| GROUP | TOTAL N = 71 |
|---|---|
| Normal | 32 |
| MCI | 18 |
| High Functioning MCI | 21 |
Summary
Seventy-one subjects, comprised of
32 cognitively normal volunteers,
and 39 subjects with mild cognitive
impairment (MCI) were included in
an analysis of the ability of the Miro
platform to distinguish subjects
with MCI from normal subjects.
32 cognitively normal volunteers,
and 39 subjects with mild cognitive
impairment (MCI) were included in
an analysis of the ability of the Miro
platform to distinguish subjects
with MCI from normal subjects.
Results
0.79 intra-class correlation
for MCI Risk Score
for MCI Risk Score
0.94 AUC for the MCI Risk Score
November 2016
Preliminary validation of Miro:
A mobile, repeatable,
self-administrable neurological
assessment platform
A mobile, repeatable,
self-administrable neurological
assessment platform
PRELIMINARY
CONCURRENT VALIDITY
CONCURRENT VALIDITY
Demographics
| DIAGNOSIS | % F/M | MEAN AGE (RANGE) | N=52 |
|---|---|---|---|
| Normal controls | 83 / 17 | 65.4 (49-89) | 19 |
| MCI | 47 / 53 | 70.4 (51-92) | 8 |
| Stroke | 20 / 80 | 62.2 (49-76) | 4 |
| Aphasia | 43 / 57 | 68.4 (58-75) | 7 |
| Alzheimer’s | 50 / 50 | 77.1 (68-86) | 0 |
| Parkinson’s | 33 / 67 | 70.3 (44-85) | 3 |
(% F/M = percent female / percent male)
Participants
Fifty-two participants were tested
on Miro modules and a battery
of analogous
comparator tests.
Analysis is based on 19 normal
participants and 33 participants
with brain impairment.
on Miro modules and a battery
of analogous
comparator tests.
Analysis is based on 19 normal
participants and 33 participants
with brain impairment.
Results
Miro module scores demonstrate
significant correlation with
comparator test scores.
Miro module scores demonstrate
significant correlation with
comparator test scores.
Sample correlations between
independent variables on Miro and
comparator tests
independent variables on Miro and
comparator tests
| MIRO | COMPARATOR TEST | SPEARMAN CORRELATION | P-VALUE |
|---|---|---|---|
| Chart-A-Course | Design Fluency (DKEFS) | 0.69 | 1.2E-06 |
| Hungry Bees | Digit Span backward (WAIS IV) | 0.65 | 3.4E-07 |
| Hungry Bees | Digit Span forward (WAIS IV) | 0.61 | 2.4E-06 |
| Treasure Tomb | Coding (WAIS IV) | 0.61 | 1.4E-08 |
| Bolt Bot | Iowa Trail Making Test | 0.54 | 1.5E-05 |
| Spy Games | Hopkins Verbal Learning Test (HVLT) | 0.52 | 5.1E-04 |
PRELIMINARY TEST-RETEST
RELIABILITY AND LEARNING EFFECTS
RELIABILITY AND LEARNING EFFECTS
Miro’s reliability was investigated
through a test-retest reliability study
that assessed
performance in normal
controls at three time points over
three months.
through a test-retest reliability study
that assessed
performance in normal
controls at three time points over
three months.
Demographics
| DIAGNOSIS | % F/M | MEAN AGE (RANGE) | N=28 |
|---|---|---|---|
| Normal controls | 83 / 17 | 65.4 (49-89) | 21 |
| High Functioning MCI | 70 / 30 | 77.4 (52-95) | 7 |
(% F/M = percent female / percent male)
Participants
Miro's test-retest reliability was
evaluated in 21 normal volunteers and
7 High Functioning MCI participants
on 3 occasions at three week intervals.
evaluated in 21 normal volunteers and
7 High Functioning MCI participants
on 3 occasions at three week intervals.
Results
The test-retest reliability intra-class
correlation coefficient (ICC) for the
MCI Risk Score was (0.79), with a
95% confidence interval of (0.65,
0.89).
This shows the stability or
reliability of measurements of
individuals’
functional abilities.
The test-retest reliability intra-class
correlation coefficient (ICC) for the
MCI Risk Score was (0.79), with a
95% confidence interval of (0.65,
0.89).
This shows the stability or
reliability of measurements of
individuals’
functional abilities.
Graph 1. Test-retest reliability
Conclusion
While traditional assessment methods have been useful in confirming moderate to severe impairment, they
have struggled to characterize mild, clinically meaningful functional differences. Preliminary findings show
promise for Miro’s platform to precisely characterize brain function. Early results on a small sample size
indicate that machine-driven approaches support the separation of overlapping groups of mildly impaired
subjects from normal controls and from each other. Test-retest reliability results demonstrate the potential to
track the signature performance of each individual over time. It is expected that with larger data sets
collected over time, these capabilities could be used to predict disease course, monitor therapeutic effects,
support differential diagnosis, describe disease sub-types, and find phenotypic markers.
have struggled to characterize mild, clinically meaningful functional differences. Preliminary findings show
promise for Miro’s platform to precisely characterize brain function. Early results on a small sample size
indicate that machine-driven approaches support the separation of overlapping groups of mildly impaired
subjects from normal controls and from each other. Test-retest reliability results demonstrate the potential to
track the signature performance of each individual over time. It is expected that with larger data sets
collected over time, these capabilities could be used to predict disease course, monitor therapeutic effects,
support differential diagnosis, describe disease sub-types, and find phenotypic markers.
